Enclomiphene side effects: what the evidence really shows

Last updated 2026-07-27

What side effects does enclomiphene actually cause?

The honest answer: we have a smaller trial dataset than you'd want for a drug this widely used off-label. The Androxal development program (Repros Therapeutics) ran several Phase 2 and Phase 3 trials in the 2010s, and those are still the best controlled-trial source we have. Across those studies, the most commonly reported adverse events were headache, nausea, diarrhea, and mood-related complaints (irritability, anxiety, or low-grade depression symptoms), plus some reports of hot flashes and fatigue ^[1]. A widely cited comparative study, Kim et al. (2016) in the Journal of Sexual Medicine, compared enclomiphene to clomiphene and testosterone therapy in hypogonadal men and reported that enclomiphene produced fewer estrogen-related and mood side effects than clomiphene, while raising testosterone comparably ^[2]. That matters because clomiphene is a mix of two isomers, enclomiphene and zuclomiphene, and zuclomiphene is the one thought to linger in the body longer and drive more of the mood and visual side effects people associate with clomiphene ^[2][3]. None of this means enclomiphene is side-effect-free. It means the side effect profile looks different from both testosterone injections and standard clomiphene, and generally milder than clomiphene on the estrogenic and mood fronts. Nobody has run a large, long-term (multi-year) safety trial in thousands of men, so anything you read stating a precise incidence rate beyond the trial data should be read with a healthy dose of skepticism. If you're adjusting a dose because of side effects, that's a conversation for the dosage guide and, more precisely, working out ranges with a dosage calculator rather than guessing.

How common is headache, nausea, or mood change on enclomiphene?

In the Androxal trial data submitted to the FDA, headache was one of the top two or three reported adverse events, alongside nausea. These weren't rare, single-digit-percentage curiosities. They showed up often enough that the FDA's review documents flagged them as things to watch, though the agency ultimately didn't approve the drug for reasons tied more to trial design and long-term safety data gaps than to a single dangerous side effect ^[1][4]. Mood changes are the side effect men worry about most, understandably, since testosterone and mood are tightly linked in most guys' minds. Some men report irritability or a flatter mood in the first few weeks. Others report the opposite: better mood as testosterone comes up from a low baseline. The Kim et al. comparative data suggests enclomiphene's mood profile is milder than clomiphene's, but 'milder than clomiphene' isn't the same as 'no mood effect' ^[2]. Hot flashes and night sweats occur in a minority of users, likely tied to shifts in the estrogen-testosterone ratio during the adjustment period. These tend to fade over 2 to 4 weeks as the body settles into a new hormonal baseline, though that timeline isn't rigorously documented in long-term studies, it's drawn from the shorter trial windows and clinical observation. Dizziness and fatigue get reported less often but do show up. If a side effect is severe, doesn't improve after 3 to 4 weeks, or comes with vision changes, that's not a 'push through it' situation. That's a call-your-prescriber situation.

Does enclomiphene affect vision, like clomiphene can?

Visual disturbances (blurred vision, light sensitivity, seeing spots or halos) are a well-documented, if uncommon, side effect of clomiphene, and it's one of the reasons some clinicians avoid clomiphene for long-term male use. Enclomiphene is the trans-isomer of clomiphene, and the visual side effects associated with clomiphene are thought to relate more to zuclomiphene, the isomer enclomiphene doesn't contain ^[3]. That said, 'thought to relate more to' is not the same as 'proven to never occur with enclomiphene.' The trial base for enclomiphene is smaller than clomiphene's decades of use, and visual side effects in clomiphene trials were uncommon to begin with, generally cited around 1.5% or lower in various reviews of clomiphene citrate use ^[3]. We don't have a clean, large-scale number specific to enclomiphene alone. The practical takeaway: if you notice blurred vision, halos around lights, or unusual visual disturbances at any point, stop the medication and contact whoever prescribed it. This is one of the few enclomiphene-adjacent side effects worth treating as an automatic pause-and-call situation rather than a wait-and-see one.

Does enclomiphene lower testosterone, cause a crash, or affect libido?

This is where the drug's actual mechanism matters. Enclomiphene is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors at the hypothalamus, which the brain reads as 'estrogen is low,' so it ramps up GnRH, then LH and FSH, which in turn drives the testes to make more testosterone naturally ^[5]. It's raising your own production, not replacing it with an external hormone. Because of that mechanism, there's no 'exogenous testosterone shutting off natural production' dynamic at play the way there is with TRT. Libido changes are still reported in some men, in both directions: some see clear improvement as total testosterone rises, others report no change or a temporary dip during the first few weeks of dose-finding. This variability is consistent with what's reported in the Kim et al. and earlier Kaminetsky trial data, where libido outcomes were mixed across the studied cohorts rather than uniformly positive ^[2][6]. There isn't a 'crash' in the TRT sense (where stopping injections drops testosterone below your pre-treatment baseline because your own axis has been suppressed). If you stop enclomiphene, the expectation, based on its mechanism, is that testosterone drifts back toward whatever your baseline was before starting, not below it. But 'expectation based on mechanism' isn't the same as 'proven in long-term discontinuation studies.' Nobody has published a rigorous multi-year discontinuation trial answering that question definitively.

Why is fertility preservation the real story with enclomiphene vs TRT?

This is the contrast that actually matters most for men choosing between TRT and enclomiphene, and it's grounded in basic reproductive endocrinology, not marketing. TRT (testosterone injections, gels, pellets) introduces testosterone from outside the body. The hypothalamus and pituitary sense that testosterone is already high, so they cut back on GnRH, LH, and FSH. LH and FSH are what drive the testes to produce both testosterone and sperm. Suppress them long enough, and sperm production drops, sometimes to zero (azoospermia), and testicular volume shrinks because the testes are no longer being stimulated to do their job ^[7]. This is well-documented; a 2016 review in the Journal of Clinical Endocrinology & Metabolism and multiple contraceptive-trial datasets on injectable testosterone confirm suppression of spermatogenesis is a consistent, expected effect of exogenous testosterone ^[7]. Enclomiphene works upstream, at the hypothalamus, blocking estrogen's negative feedback signal. That keeps GnRH, LH, and FSH flowing, sometimes at higher levels than baseline, which is why testosterone rises without the testes being told to power down. Because LH and FSH stay active, testicular size and sperm production tend to be preserved, which is the core reason younger men or men actively trying to conceive often get steered toward enclomiphene instead of TRT ^[2][5]. 'Tends to preserve' is deliberately careful language. The trial data supports testosterone increases alongside maintained LH/FSH and, in the studies that measured it, better preservation of testicular volume compared to TRT groups ^[2][6]. But large trials weren't designed as fertility outcome studies, tracking live birth rates or sperm counts over years. If you are actively trying to conceive, that's a conversation for a reproductive endocrinologist, with semen analysis before and during treatment, not a guess based on mechanism alone. | Factor | Enclomiphene | Exogenous TRT |

Is enclomiphene FDA-approved, and does that affect safety?

No. Enclomiphene is not FDA-approved as a standalone medication. The company that developed it for male hypogonadism, Repros Therapeutics, ran the Androxal program through Phase 3 trials but never secured FDA approval, and the program was ultimately discontinued ^[1][4]. What's sold today under names like Enclomiphene Direct is a compounded product, made by a compounding pharmacy based on a prescription, not a drug that went through the FDA's standard New Drug Application approval and post-market surveillance process. That distinction matters for how you think about safety data. FDA-approved drugs come with a package insert built on the full trial dataset submitted to the agency, plus years of post-market adverse event reporting through the FDA Adverse Event Reporting System (FAERS). Compounded enclomiphene doesn't have that same standardized insert or that scale of post-market surveillance, because it was never approved as a distinct commercial product. The safety data that does exist comes from the Androxal clinical trials themselves and from published comparative studies like Kim et al., not from a decade of monitored, approved, real-world prescribing ^[1][2]. That doesn't mean compounded enclomiphene is unsafe. It means the safety picture is built on a smaller, older trial base rather than a mature FDA-monitored drug history, and you should treat claims about long-term safety accordingly, with appropriate caution rather than blanket reassurance. Compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act are regulated, but differently from manufacturers of approved drugs; 503A pharmacies compound for individual patients based on a valid prescription, and 503B outsourcing facilities can compound in larger batches under separate FDA oversight requirements ^[8]. Where you get your prescription filled, and whether that pharmacy is provider-reviewed and properly licensed, is not a minor detail.

How is enclomiphene different from clomiphene, and does that change the side effects?

Clomiphene citrate is a mix of two stereoisomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer). When your grandmother's generation, or more likely your own doctor today, prescribes Clomid for a man, that's clomiphene, both isomers together ^[3]. Enclomiphene, sold as a standalone compounded product, is just the trans-isomer. The working theory in the literature is that enclomiphene does most of the testosterone-raising work, while zuclomiphene lingers in the body far longer (it has a much longer half-life) and is thought to contribute more to the mood, visual, and estrogenic side effects associated with clomiphene use ^[3]. The Kim et al. 2016 comparative trial supports this: enclomiphene raised testosterone as effectively as clomiphene while showing a more favorable side effect profile in the areas studied ^[2]. Practically, this means if you had a rough experience on clomiphene (visual disturbances, mood swings, bloating), enclomiphene alone might sidestep some of that, since you're not getting the zuclomiphene component. But 'might' is doing real work in that sentence. Isomer-specific side effect data is suggestive, not exhaustively proven across large populations, and individual response still varies.

Who should avoid enclomiphene, or use extra caution?

A few groups come up consistently in the clinical literature and prescribing guidance around SERMs and male hormone therapy. Men with a history of blood clots or clotting disorders should discuss this carefully with a prescriber, since SERMs as a class (including tamoxifen, a related compound used in breast cancer treatment) carry some association with thromboembolic events in the broader SERM literature, even though the specific enclomiphene trial data didn't flag this as a dominant signal ^[1]. Men with active liver disease, since the drug is metabolized hepatically. Men with a history of pituitary or hypothalamic dysfunction, since the drug's entire mechanism depends on a functioning hypothalamic-pituitary-gonadal axis responding appropriately, and it won't work (and may not be appropriate to try) if that axis is already damaged. Men with known hypersensitivity to clomiphene or its components. Men with a personal or strong family history of certain hormone-sensitive conditions should raise that explicitly with their prescriber before starting, given the drug's action on estrogen receptors, even though enclomiphene isn't used in those conditions the way tamoxifen is. This is not a supplement. It requires baseline bloodwork (total and free testosterone, LH, FSH, estradiol) and a prescriber who is actually reviewing your labs before and during treatment, more than filling a request. That's the whole point of a provider-reviewed process rather than buying from an unverified source.

What does a typical enclomiphene side effect timeline look like?

Most men who tolerate enclomiphene well report the bulk of side effects, if any, clustering in the first 2 to 4 weeks as hormone levels shift. This isn't from a formal published timeline study, it's the pattern described across clinical observation and the shorter trial windows in the Androxal program, so treat it as a general expectation rather than a guarantee ^[1][6]. Week 1 to 2: this is when headache, mild nausea, and initial mood fluctuation are most likely to show up, as LH and FSH ramp up and testosterone begins climbing. Week 3 to 4: bloodwork typically gets rechecked around here in a well-run protocol, and most men report early side effects (headache, nausea) easing as the body adjusts to the new hormonal baseline. Month 2 and beyond: side effects that persist past 4 to 6 weeks, rather than fading, are worth a dose reassessment with your prescriber rather than pushing through. This is also when problems tied to dosing errors (too high a dose, inconsistent timing) tend to surface, which is why getting your protocol right from day one matters. If you haven't nailed down your reconstitution or dosing process, the reconstitution guide and notes on injection sites are worth reviewing before you start, even though enclomiphene itself is most commonly dosed orally in compounded form, some protocols do vary.

How do enclomiphene's side effects compare to TRT's side effects?

They're genuinely different risk profiles, more than different degrees of the same thing. TRT's well-documented risks include suppressed sperm production and reduced testicular size (discussed above), polycythemia (thickened blood from elevated red blood cell count, which is monitored via hematocrit and can raise clotting risk if unmanaged), and, for some formulations, acne or skin reactions at injection or application sites ^[7]. TRT also creates a dependency dynamic: your natural production is suppressed while on it, so stopping can mean a period of low testosterone while your own axis restarts, sometimes for months. Enclomiphene's most reported issues, per the trial data discussed above, are headache, nausea, mood fluctuation, and occasional hot flashes, without the same suppression-and-restart dynamic, because it works by stimulating your own axis rather than replacing its output ^[1][2][5]. It also doesn't carry the same well-established polycythemia signal that testosterone injections do, in part because the physiologic dynamics of the two therapies differ. Neither profile is 'safer' as a blanket statement. It depends on your goals. A 45-year-old man who is done having kids and wants the most direct route to symptom relief may reasonably choose TRT despite the fertility tradeoff. A 30-year-old man who wants his testosterone up but is planning to have children in the next few years has a real, mechanism-backed reason to consider enclomiphene instead, discussed with a prescriber who understands both options.

What should I do if I experience side effects on enclomiphene?

Mild, early side effects (headache, mild nausea, brief mood dip) that show up in the first 2 to 3 weeks and are tolerable: many men ride these out while getting rechecked labs at the 4 to 6 week mark, per a typical monitoring protocol. Moderate or persistent side effects past 4 to 6 weeks: this is a dose conversation, not a 'wait longer' situation. Your prescriber may adjust dose or frequency based on your labs and symptoms. This is exactly why working from a real dosage guide and a dosage calculator matters more than eyeballing a protocol you read on a forum. Severe or acute symptoms, vision changes, chest pain, calf swelling or pain (a possible clot sign), severe mood changes, or anything that feels wrong: stop the medication and get medical attention. Don't wait for your next scheduled check-in. The most reliable path through any of this is starting with a provider who reviews your labs and history before prescribing, and who's available when something feels off partway through your cycle length. That's the actual value of a provider-reviewed telehealth process like the one Enclomiphene Direct uses: not a shortcut around the drug's real profile, but a person checking your numbers before and during treatment, working with a compounding pharmacy that fills the prescription rather than a company just shipping product to anyone who asks.

Frequently asked questions

What are the most common side effects of enclomiphene?

Across the Androxal clinical trial program, the most frequently reported side effects were headache, nausea, and mood-related changes like irritability, along with occasional hot flashes and fatigue. These were generally mild to moderate and, per comparative research, less frequent than the side effects seen with standard clomiphene citrate.

Does enclomiphene cause weight gain?

Weight gain isn't listed among the primary adverse events reported in enclomiphene's clinical trial data. Some men report fluid retention or appetite changes as testosterone shifts, but there's no strong trial evidence tying enclomiphene directly to weight gain the way some other hormone therapies are associated with fluid retention.

Can enclomiphene cause erectile dysfunction?

Enclomiphene raises testosterone, which more often helps than harms erectile function in men with low testosterone to begin with. Some men report no change in the first few weeks while hormone levels stabilize. It isn't reported as a common trial adverse event, but individual response varies and any persistent ED should be discussed with your prescriber.

Is enclomiphene safer than TRT?

They carry different risks, not a simple safer/riskier ranking. Enclomiphene tends to preserve fertility and testicular size since it works upstream in the hormone axis, while TRT can suppress sperm production and cause testicular shrinkage. TRT has well-documented risks like polycythemia. Which is more appropriate depends on your fertility goals and overall health profile.

Will enclomiphene affect my sperm count or fertility?

Because enclomiphene maintains or raises LH and FSH rather than suppressing them, it generally preserves sperm production, unlike exogenous TRT which commonly suppresses it. That said, large trials weren't designed as fertility-outcome studies tracking sperm counts over years, so men actively trying to conceive should get baseline and follow-up semen analysis with a reproductive specialist.

Is enclomiphene FDA-approved?

No. Enclomiphene is not FDA-approved as a standalone drug. Repros Therapeutics developed it under the name Androxal and ran it through Phase 3 trials, but the program never reached FDA approval. What's available today is compounded by pharmacies based on an individual prescription, not sold as an approved commercial drug product.

What's the difference between enclomiphene and clomiphene side effects?

Clomiphene contains two isomers, enclomiphene and zuclomiphene. Zuclomiphene has a much longer half-life and is thought to drive more of clomiphene's mood and visual side effects. Comparative trial data (Kim et al., 2016) found enclomiphene alone produced fewer mood and estrogen-related side effects than clomiphene while raising testosterone comparably.

Can enclomiphene cause vision problems?

Visual disturbances are a known, though uncommon, side effect associated with clomiphene, more likely tied to the zuclomiphene isomer that enclomiphene doesn't contain. Enclomiphene-specific data on this is limited. Any blurred vision, light sensitivity, or visual disturbance while on enclomiphene warrants stopping the medication and contacting your prescriber right away.

How long do enclomiphene side effects last?

Most reported side effects, headache, nausea, mild mood changes, cluster in the first 2 to 4 weeks as hormone levels adjust and tend to ease as the body reaches a new baseline. This pattern comes from clinical observation and trial timelines rather than a dedicated long-term side-effect study, so individual timelines vary.

Does enclomiphene cause a testosterone crash when you stop?

Because enclomiphene stimulates your own hormone production rather than replacing it, the expectation based on its mechanism is that testosterone drifts back toward your pre-treatment baseline after stopping, not below it, unlike the suppression-and-restart pattern seen after stopping TRT. No large, rigorous discontinuation trial has confirmed this precisely, though.

Who shouldn't take enclomiphene?

Men with active liver disease, a history of blood clots, pituitary or hypothalamic dysfunction, or known hypersensitivity to clomiphene should discuss these specifically with a prescriber before starting. Baseline bloodwork and a provider actually reviewing your history and labs, rather than self-directed use, is the standard of care here.

Is compounded enclomiphene regulated?

Compounded enclomiphene is prepared by pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which regulate compounding differently than FDA-approved manufactured drugs. It doesn't go through the same New Drug Application approval or the scale of post-market surveillance an approved drug gets, so sourcing from a licensed, provider-reviewed pharmacy matters.

Sources

1. Kim et al., Journal of Sexual Medicine (2016): Comparative side effect profile of enclomiphene vs clomiphene and testosterone therapy in hypogonadal men
2. MedlinePlus, Clomiphene: Clomiphene citrate composition, known visual disturbance side effects, and general side effect profile
3. ClinicalTrials.gov, Repros Therapeutics Androxal Phase 3 study record: Androxal (enclomiphene) Phase 3 clinical trial existed and was conducted by Repros Therapeutics for secondary hypogonadism
4. Wiehle et al., mechanism review of enclomiphene as SERM, Fertility and Sterility: Enclomiphene mechanism as SERM acting at hypothalamus to increase LH, FSH, and endogenous testosterone
5. Kaminetsky et al., Journal of Sexual Medicine (2013): Enclomiphene citrate trial data on testosterone, LH/FSH response, and libido outcomes in hypogonadal men
6. Journal of Clinical Endocrinology & Metabolism, review of exogenous testosterone effects on spermatogenesis: Exogenous testosterone therapy suppresses spermatogenesis and can cause azoospermia and reduced testicular volume
7. Kolettis et al., pharmacokinetics of enclomiphene and zuclomiphene isomers: Zuclomiphene has a longer half-life than enclomiphene and is implicated in clomiphene's estrogenic and mood side effects
8. MedlinePlus, Tamoxifen: SERM class drugs such as tamoxifen carry an associated risk of thromboembolic (blood clot) events